Where Will AbbVie Be in 5 Years?
In some ways, (NYSE: ABBV) isn't the same company it was five years ago. Sure, it's still in the biopharmaceuticals business. However, AbbVie has a new CEO. More importantly, it no longer depends on Humira for roughly 37% of total revenue.
Today, AbbVie can see its Humira patent cliff in the rearview mirror. But what does the view look like through the front windshield? Where will AbbVie be in five years?
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Stock
€177.80
0.230%
With 32 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 209 € there is a slightly positive potential of 17.55% for AbbVie Inc. compared to the current price of 177.8 €.
